Viewing Study NCT01818362



Ignite Creation Date: 2024-05-06 @ 1:26 AM
Last Modification Date: 2024-10-26 @ 11:04 AM
Study NCT ID: NCT01818362
Status: COMPLETED
Last Update Posted: 2015-12-15
First Post: 2013-03-18

Brief Title: A Phase I Study of Candidate Influenza Vaccines MVA-NPM1 and ChAdOx1 NPM1
Sponsor: University of Oxford
Organization: University of Oxford

Study Overview

Official Title: A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NPM1 and ChAdOx1 NPM1
Status: COMPLETED
Status Verified Date: 2015-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This will be a randomised observational phase 1 study in 48 healthy volunteers aged 18-50 The study is assessing safety and immunogenicity of viral vectored vaccines ChAdOx1 NPM1 and MVA NPM1 in heterologous prime-boost regimens A crossover design will allow comparison of the two vaccines Volunteers will be divided into 4 groups n12 in each group Groups will be recruited simultaneously to control for seasonal changes in influenza This is because at certain times of year there is likely to be a higher naturally acquired T cell response to influenza than at other times due to circulating influenza virus in the community

The study has been extended to include 2 additional groups group 5 6 each containing 12 healthy adults aged 50 years or above Group 5 will receive ChAdOx 1 NPM1 on day 0 and group 6 will receive this with an additional boost of MVA-NPM1 8 weeks later
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None